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 Abstract. Previously we have demonstrated that a recombinant
Newcastle disease virus (NDV) carrying the transgene EGFP
can be retargeted to IL-2 receptor positive tumor cells by a
bispecific fusion protein ·HN-IL-2 in vitro. The purpose of
the present study was to investigate the specificity and
efficiency of gene delivery to tumor cells in vivo via this
modified RNA virus. Prior ex vivo infection of murine
lymphoma cells by the modified virus resulted in selective
EGFP expression in IL-2R+ target tumor cells in vivo. Direct
fluorescence microscopy and immunohistology showed viral
replication in target positive tumor tissue resulting in much
more EGFP expression than in target negative tumor tissue,
24 h after intratumoral injection of the ·HN-IL-2 modified
NDV. A quantitative real-time RT-PCR for EGFP mRNA.
confirmed the selective gene expression in IL-2R+ tumor cells.
Biodistribution studies showed that EGFP transgene delivery
was reduced by 35-100% in liver, spleen, kidney, lung and
thymus by the modified virus, while 98% of the transgene
was delivered to IL-2R+ tumors. In conclusion, the modification
of NDV by the bispecific protein does not compromise
severely the efficiency of gene delivery into IL-2R-positive
tumors, but greatly reduces viral gene expression in IL-2R-
negative tumors and in normal tissues.
Introduction
Newcastle Disease Virus (NDV), an avian negative-strand
RNA virus of the family Paramyxoviridae, has characteristics
which are very attractive for cancer therapy (1-3). First, it
shows tumor selective replication. Integral to the life cycle
of all RNA viruses is the formation of double-strand RNA
(dsRNA). dsRNA activates Toll-like receptor 3 and a spectrum
of cellular defense mechanisms including the activation of
RNA binding protein kinase (PKR) and the release of inter-
feron ·/ß (4-6). Since tumor cells are frequently defective in
their PKR signaling and interferon response pathways, they
are relatively permissive for infection by RNA viruses. Second,
its replication occurs in the cytoplasm of host cells and thus
avoids potentially deleterious interactions with the genomic
DNA. Third, reverse genetics techniques allow the modification
of the viral RNA genome. Several recombinant NDV carrying
transgenes, such as enhanced green fluorescent protein (EGFP)
or human secreted alkaline phosphatase were generated (7-9).
Fourth, clinical applications of this virus are numerous. They
are mainly based on two strategies. One is exploiting the
immune stimulatory properties of NDV in the form of auto-
logous tumor cell vaccine (ATV-NDV) to treat solid tumors.
Clinical studies based on this strategy revealed significant
improvement of patient survival (10-13). Another clinical
application makes use of the oncolytic properties of some NDV
strains (14,15).
Two main drawbacks limit the use of NDV in vivo. First,
NDV binds to every cell, whether it is a normal or a tumor
cell since the sialic acid-containing receptors for NDV are
ubiquitously expressed on cell surfaces. Although NDV
shows a preferential replication in tumor cells, its binding to
normal cells might compromise its therapeutic effect and
cause side effects when administered systemically in vivo.
Second, in vivo administration of very high doses of NDV
could produce toxic side effects.
To avoid the binding of NDV to normal cells and to
selectively target it to tumor cells, we suggest to modify its
properties by adding a linker molecule to its surface. We have
previously shown in vitro that, by doing so, a recombinant
NDV could be retargeted selectively to marker-defined tumor
cells (16,17). For this, we pre-incubate the virus with a specially
designed recombinant bispecific fusion protein (·HN-IL-2).
As described before, ·HN-IL-2 binds to the HN molecule
of the virus, thereby neutralising it, and to the IL-2 receptor
(IL-2R), which is used as a tumor marker. Thus the protein
assures the selective binding of the virus to the targeted tumor
cells.
In this study, we investigated ex vivo and in vivo the
delivery of genes to tumor and normal tissues via such a
modified NDV vector.
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Materials and methods
Cells, antibodies and bispecific fusion protein. The metastatic
mouse tumor cell line p11-R-Eb was obtained after i.p.
passages of the non-metastatic Eb lymphoma cells into
DBA/2 mice (18). The cells were propagated in RPMI-1640
medium supplemented with 10% foetal calf serum (FCS)
at 37˚C in a humidified atmosphere of 5% CO2.
Polyclonal rabbit anti-NDV serum was prepared by
immunizing rabbit four times s.c. with 40000 HU/ml NDV-
Ulster mixed 1:1 with incomplete Freund's adjuvant. Pre-
immune serum and the antiserum were heat-inactivated (for
45 min at 56˚C), aliquoted and stored at -20˚C.
The bispecific fusion protein ·HN-IL-2 was constructed
by fusion of a single-chain antibody cloned from a neutralizing
HN specific hybridoma linked to the human cytokine IL-2 as
described previously (16).
Recombinant NDFL-EGFP. The recombinant NDFL-EGFP
was derived genetically from non-lytic strain NDV-LaSota by
reverse genetics as described previously (7,16,19). The virus
was propagated in embryonated chicken eggs, harvested
from the allantoic fluid, purified by ultracentrifugation and
cryopreserved in aliquots at -70˚C. The virus was quantified by
a hemagglutination assay. One hemagglutination unit (HU) is
defined as the smallest virus concentration leading to visible
sheep erythrocyte agglutination.
In vitro infection of tumor cells with NDV. Cell suspensions
were washed twice with FCS-free RPMI-1640 medium and
1x106 cells were incubated with 10 HU of NDV or the same
doses of modified NDV/·HN-IL-2 in a final volume of 100 µl
for 1 h at 37˚C in a CO2 incubator. During the incubation, cells
were shaken every 15 min. The cells were then washed twice
and further cultured for 24 h to allow for viral replication. Viral
replication was then evaluated as EGFP fluorescence by flow
cytometry and FACS data were analysed with CellQuest soft-
ware (Becton-Dickinson, Heidelberg, Germany).
1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine
iodide (DiR) labeling. To differentiate the Eb-M7 cells from
the mouse peritoneal cavity cells, Eb-M7 cells were labelled
with DiR (Molecular Probes, Leiden, The Netherlands) which
has absorption and emission maxima in the near infrared
region, where non-labelled cells are optically transparent.
After 2 washes, the Eb-M7 cells were suspended at a density
of 1x106/ml in serum-free medium. Two µl of a 50 mg/ml stock
solution of DiR was then added to the cells. After incubation
for 15 min at 37˚C, the cells were washed twice with pre-
warmed serum-free medium.
Ex vivo infection of tumor cells with NDV. Pathogen-free
DBA/2 mice were obtained from Charles River GmbH (Wiga,
Germany) and kept under pathogen-free conditions at the
DKFZ animal facilities (Heidelberg, Germany). All procedures
involving mice was approved by the Animal Care and Use
Committee of the German Cancer Research Center. DiR-
labeled Eb-M7 cells (1x107) which were incubated either
with 100 HU NDFL-EGFP or modified NDFL-EGFP/
·HN-IL-2 for 1 h at 37˚C in vitro were then injected into the
peritoneal cavity of mice that received whole body irradiation
at 4.5 Gy 1 day before (the procedure here is named ex vivo
modification). For the negative controls, NDV was replaced
by PBS. After 24 h, cells in mouse peritoneal cavity were
harvested by lavage technique using ice-cold PBS containing
5% FCS. The EGFP fluorescence of DiR-positive cells from
the mouse peritoneal cavity was analysed by flow cytometry.
Intratumoral EGFP expression and immunohistochemistry
(IHC) with NDV specific antibody. DBA/2 mice received s.c.
implants of 5x106 syngeneic Eb-M7 (IL-2R·+) or Eb-M7
(IL-2R·-) cells/100 µl PBS. One week after tumor cell
implantation, NDFL-EGFP (100 HU/100 µl) or modified
NDFL-EGFP/·HN-IL-2 (100 HU/100 µl) or an equivalent
volume of PBS was injected intratumorally. To assess EGFP
expression and virus replication, mice were euthanized at 1 or
24 h after virus injection. Tumors were harvested and fixed
overnight in PBS containing 1.5% paraformaldehyde and
20% sucrose. Section (6-µm) were prepared from frozen
tissues previously embedded in Tissue-Tek OCT Compound
(Sakura Finetek Europe B.V., distributed by Vogel GmbH,
Giessen, Germany). EGFP was visualized by fluorescence
microscopy using an EGFP filter. Sections on slides coated
with 3-triethoxysilylpropylamine (Sigma, Taufkirchen,
Germany) were subjected to IHC using rabbit polyclonal
anti-NDV serum (1:800 dilution), followed by chicken anti-
rabbit Ig (H+L) Alexa Fluor 594 (1:400 dilution) (Molecular
Probes). IHC sections were counterstained with 4',6-diamidino-
2-phenylindole (DAPI).
Quantification of the in vivo EGFP expression by quantitative
real-time reverse transcriptase-polymerase chain reaction
(RRT-PCR). DBA/2 mice bearing either Eb-M7 (IL-2R·+) or
Eb-M7 (IL-2R·-) tumors were injected intratumorally either
with 100 HU/100 µl of NDFL-EGFP or modified NDFL-
EGFP/·HN-IL-2. Other DBA/2 mice bearing both Eb-M7
(IL-2R·+) and Eb-M7 (IL-2R·-) tumors on their right and left
flanks respectively were injected i.v. with 5000 HU of
NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2 into the
tail vein. Twenty-four hours after injection, i.v. injected-mice
were perfused transcardially through the aorta with DEPC-
treated PBS until lung, liver and kidney turned pale. Tumors
(IL-2R·+ and IL-2R·-), liver, spleen, kidney, lung and thymus
from i.v. injected-mice and tumors from intratumoral-injected
mice were removed and immediately submerged in RNAlater
RNA Stabilization solution (Qiagen GmbH, Hilden, Germany).
RNA was extracted following the Qiagen RNeasy procedure
for animal tissue (Qiagen). Then, first-strand cDNA was
synthesized from it using the SuperScriptTM II RNase H-
Reverse Transcriptase (Invitrogen).
RRT-PCR was carried out using a Gene Amp 5700
Sequence Detection System (Applied Biosystems GmbH,
Weiterstadt, Germany). Amplifications were run in separate
tubes to illustrate relative quantitation of EGFP and normalized
with an endogenous control, mouse ß-actin. Primers for
EGFP (sense, 5'-ATC ATG GCC GAC AAG CAG AAG
AAC-3'; antisense, 5'-GTA CAG CTC GTC CAT GCC GAG
AGT-3') (20) and mouse ß-actin (sense, 5'-ACG GCC AGG
TCA TCA CTA TTG-3'; antisense, 5'-AGG ATT CCA TAC
CCA AGA AGG AA-3') were synthesized by the German
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Cancer Research Center. Each RRT-PCR was performed in
a 25 µl reaction mixture containing 17.5 µl Master Mix
(qPCRTM Core Kit for SYBR Green I, Eurogentec, Köln,
Germany), 300 nM of each primer for EGFP or 300 nM
(sense) and 900 nM (antisense) for ß-actin. cDNA from
PBS-treated mice was used as negative controls and was
included in each set of experiments. A common threshold
was set in the exponential phase of the PCR reactions to
determine a specific threshold cycle (CT) number for each
sample. Comparative CT method was used to relatively quantify
the EGFP expression.
Results
Cloning of Eb-M7 (IL-2R
 
·+) and Eb-M7 (IL-2R·-) cells. To
prove the principle of retargeted virus infection of tumors we
decided to first select target positive and target negative
tumor cell lines from the mouse lymphoma p11-R-Eb. This cell
line contains IL-2R· positive and negative cells as revealed
by staining with mouse mAb CD25-PE and FACS analysis
(Fig. 1A). After three rounds of sorting we were able to
select a high IL-2R· expressing cell population (here called
Eb-M7 IL-2R·+) and a very low IL-2R·-expression cell
population (here called Eb-M7 IL-2R·-). One hundred percent
of Eb-M7 (IL-2R·+) cells were positive for IL-2R· and the
mean fluorescence intensity (FI) for IL-2R· was enhanced
3.5-fold in comparison to the parental p11-R-Eb cells. In
contrast, the Eb-M7 (IL-2R·-) cells were completely negative
for IL-2R· expression. Both cell populations were stable
with regard to their expression of IL-2R over many culture
passages.
Enhanced-retargeted gene transfer via NDFL-EGFP by
·HN-IL-2. We first tested the effect of the bispecific fusion
protein ·HN-IL-2 on the tropism of NDV. For that, 10 HU of
NDFL-EGFP was pre-incubated with 12 µg/ml of ·HN-IL-2
for 1 h on ice. This modified virus was then used to infect
p11-R-Eb, Eb-M7 (IL-2R·+) and Eb-M7 (IL-2R·-) cells for
24 h at 37˚C. FACS analysis (Fig. 1B) showed that the
relative EGFP expression was enhanced by a factor 3.2 in
the Eb-M7 (IL-2R·+) cell population in comparison to the
parental p11-R-Eb cells. The relative EGFP expression in
the Eb-M7 (IL-2R·-) cell population was only 2.6%. We
conclude that virus binding and replication was improved in
IL-2R·+ cells and reduced considerably in the IL-2R·- cells.
Retargeted gene expression in vivo after ex vivo infection. To
evaluate in vivo the retargeted gene transfer, DiR-labeled
Eb-M7 (IL-2R·+) or Eb-M7 (IL-2R·-) cells were infected
ex vivo either with native or modified NDFL-EGFP. They
were then given i.p. to DBA/2 mice which were Á-irradiated
with 4.5 Gy one day before injection. After 24 h, peritoneal
cells were harvested and DiR-positive cells were gated and
analyzed by flow cytometry for EGFP expression. As shown
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Figure 1. (A), IL-2R· expression on parent p11-R-Eb and cloned Eb-M7
cell lines. 106 p11-R-Eb, Eb-M7 (IL-2R·+) or Eb-M7 (IL-2R·-) cells were
washed twice with FACS buffer (PBS containing 5% FCS and 0.1% NaN3)
and then incubated with mouse mAb CD25-PE for 30 min on ice in the dark.
After being washed twice with FACS buffer, cells were analyzed by flow
cytometry with CellQuest software. Cells without staining (grey peak) were
used as negative controls. (B), Enhanced-retargeted EGFP expression in
Eb-M7 (IL-2R·+) cells in vitro. NDFL-EGFP (10 HU) was pre-incubated with
12 µg/ml of ·HN-IL-2 for 1 h on ice, then further incubated with 106 p11-
R-Eb, Eb-M7 (IL-2R·+) or Eb-M7 (IL-2R·-) cells for 1 h at 37˚C. After
being washed twice with medium, cells were further cultured for 24 h. Parallel
experiments were done with same dose of native NDFL-EGFP. Cells were
analyzed for EGFP fluorescence by flow cytometry. The percentage of
retargeted EGFP expression was calculated as the ratio of the percentage of
EGFP-positive cells infected with the modified NDFL-EGFP/·HN-IL-2 to
the percentage of EGFP-positive cells infected with the native NDFL-EGFP.
A
B
in Fig. 2, 29.1% of Eb-M7 (IL-2R·+) cells and only 1.2% of
Eb-M7 (IL-2R·-) cells were infected by NDFL-EGFP/
·HN-IL-2. In contrast, when using native NDFL-EGFP there
was almost a similar percentage of Eb-M7 (IL-2R·+) and
Eb-M7 (IL-2R·-) cells (69.7-60.3%) infected. We conclude
that ex vivo infection of tumor cells by the modified virus leads
to selective replication of the virus in the IL-2R·+ target
positive tumor cells.
Intratumoral NDV infection and EGFP expression in situ. In
order to test viral infection of tumor cells in vivo, DBA/2
mice bearing tumors of 0.5 cm diameter were injected intra-
tumorally with 100 HU of native NDFL-EGFP or modified
NDFL-EGFP/·HN-IL-2. Tumors were dissected at 1 or 24 h
after virus application and subjected to immunohisto-
chemistry (IHC) or to direct fluorescence microscopy. IHC
revealed that tumor tissues from 1 h had virus bound to cell
membranes (Fig. 3b), while tumor tissues from 24 h had
virus located in the cytoplasm (Fig. 3c). After 24 h, viral
replication in the tumor tissue caused in some areas tumor
necrosis (high expression of viral antigens overlapping with
an area of reduced cell nuclei, Fig. 3d).
When analyzing the tumor sections by fluorescence
microscopy, no EGFP fluorescence was observed in tumors
harvested 1 h after virus inoculation (data not shown). In
contrast, a strong EGFP fluorescence could be observed 24 h
later. When using modified virus (NDFL-EGFP/·HN-IL-2)
instead of NDFL-EGFP, target positive tumors expressed much
more EGFP than target negative tumors (Fig. 4, right panels).
Establishment of quantitative RRT-PCR for EGFP detection.
To achieve a high degree of sensitivity for the quantification
of the EGFP signal, we established a real-time RT-PCR
(RRT-PCR) assay. Mouse ß-actin served as endogenous
control. Fig. 5a shows kinetics of RRT-PCR reactions obtained
for the EGFP and ß-actin genes from Eb-M7 (IL-2R·+) cells
that were infected in vitro with NDFL-EGFP. Melting
temperatures of dissociation curves (Fig. 5b) indicated that
the amplicons were specific for EGFP and ß-actin, respectively.
To determine whether the two amplicons have the same
amplification efficiency, we analyzed how the difference in
threshold cycles (CT) obtained with EGFP and ß-actin (∆CT)
varied when the template was diluted. Theoretically, if the
efficiencies of the two genes are approximately equal, the
plot of log input amount versus ∆CT has a very low slope
(<0.1). As shown in Fig. 5c, regression analysis of CT data for
EGFP and ß-actin showed a horizontal line with a negligible
absolute slope (0.09). This demonstrates that ß-actin can serve
as a reliable reference to normalize the EGFP measurements.
In vivo determination of EGFP-mRNA by quantitative
RRT-PCR after intratumoral virus inoculation. To quantify
transgene expression delivered by the modified recombinant
NDFL-EGFP/·HN-IL-2 in comparison to the native NDFL-
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Figure 2. In vivo retargeted EGFP transgene expression via NDFL-EGFP by ·HN-IL-2 to tumor cells after ex vivo modification. DBA/2 mice were given
whole body irradiation at 4.5 Gy 1 day before i.p. injection of 107 DiR-labeled Eb-M7 (IL-2R·+) or Eb-M7 (IL-2R·-) cells which were incubated ex vivo either
with 100 HU NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2 for 1 h at 37˚C. PBS was used as negative control instead of virus. After 24 h, cells in mouse
peritoneal cavity were harvested by lavage technique using ice-cold PBS containing 5% FCS. DiR-positive cell population was evaluated by determination of
the EGFP fluorescence by FACS analysis.
EGFP in tumor tissues, cDNA from whole Eb-M7 (IL-2R·+)
and Eb-M7 (IL-2R·-) tumors was synthesized by reverse trans-
cription of RNA extracted from the tumors. EGFP expression
in virus-treated tumors relative to PBS-treated tumors was
calculated using the comparative CT method (Table I). A
prominent retargeted EGFP transgene expression was detected
in Eb-M7 (IL-2R·+) cells infected with modified NDFL-EGFP/
·HN-IL-2. In comparison to EGFP expression in Eb-M7
(IL-2R·+) tumors infected with native NDFL-EGFP, a 6.3-fold
higher gene delivery occurred in such tumors when infected
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Figure 3. In situ intratumoral virus infection with modified NDFL-EGFP/·HN-IL-2 in Eb-M7 (IL-2R·+). DBA/2 mice bearing Eb-M7 (IL-2R·+) tumors (0.5 cm)
on their flanks received intra-tumorally NDFL-EGFP/·HN-IL-2 (100 HU/100 µl). Mice were sacrificed at 1 or 24 h after virus injection. Tumor sections were
stained with rabbit polyclonal anti-NDV serum, followed by Alexa 594-conjugated chicken anti-rabbit secondary antibodies and DAPI for nuclear staining
before being analyzed by fluorescence microscopy. Tumor treated with PBS was used as negative control (a). Virus binding on the cell membrane was
observed at 1 h (b). After 24 h, virus was visualized in the cytoplasm and interstitium (c). Necrosis in part of the tumor was induced by virus replication (d).
Figure 4. Visualization of EGFP expression by fluorescence microscopy. DBA/2 mice bearing Eb-M7 tumors (0.5 cm) on their flanks received intratumorally
either NDFL-EGFP or NDFL-EGFP/·HN-IL-2 (100 HU/100 µl). Mice were sacrificed at 24 h after virus injection. Tumor sections were observed directly
under the fluorescence microscope. Tumor treated with PBS was used as negative control.
by NDFL-EGFP/·HN-IL-2. Gene delivery via modified virus
to Eb-M7 (IL-2R·-) cells was only 1.2% compared to target
positive cells.
Biodistribution of the EGFP transgene after intravenous
application of NDV. DBA/2 mice bearing Eb-M7 (IL-2R·+)
and Eb-M7 (IL-2R·-) tumors on their right and left flanks
respectively received i.v. either 5000 HU of NDFL-EGFP or
modified NDFL-EGFP/·HN-IL-2. Twenty-four hours later,
the organ distribution of the EGFP mRNA was determined
by RRT-PCR (Table II). We observed relatively high levels
of EGFP mRNA in the lung, thymus, liver and spleen. Some
EGFP mRNA could also be detected in tumors although at
lower amounts. Compared to the native NDFL-EGFP, 98%
of transgene was delivered to Eb-M7 (IL-2R·+) tumors by
modified NDFL-EGFP/·HN-IL-2, while 28% of transgene
was found in Eb-M7 (IL-2R·-) tumors. Importantly, the
EGFP-mRNA expression decreased significantly (by 35-
100%) in normal organs when the virus NDFL-EGFP was
modified with ·HN-IL-2.
Discussion
In this study we demonstrate that recombinant NDV, when
modified by the bispecific fusion protein ·HN-IL-2, is an
efficient vector for selective gene transfer into IL-2R-positive
tumor cells both ex vivo and in vivo. The modification of NDV
by the bispecific protein does not compromise severely the
efficiency of gene delivery into IL-2R-positive tumors, but
greatly reduces viral gene expression in IL-2R-negative tumors
and in normal tissues.
Much attention has recently been focused on RNA
viruses as vectors for tumor therapy, including measles virus,
vesicular stomatitis virus (VSV), reovirus, and NDV. These are
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Table I. Quantification of the EGFP expression in tumors by
RRT-PCR after intratumoral injection of native or modified
NDFL-EGFP.
–––––––––––––––––––––––––––––––––––––––––––––––––
Tumor EGFP copies % retargeted EGFP
expression
–––––––––––––––––––––––––––––––––––––––––––––––––
(A) native virus
IL-2R·+ 44762.4
IL-2R·- 5345894.7
(B) modified virus
IL-2R·+ 282913.2 632.0
IL-2R·- 65536.0 1.2
–––––––––––––––––––––––––––––––––––––––––––––––––
DBA/2 mice bearing either Eb-M7 (IL-2R·+) or Eb-M7 (IL-2R·-)
tumors (0.5 cm) on their flanks received intratumorally native
NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2 (100 HU/100 µl).
Mice were sacrificed at 24 h after virus injection and tumors were
analyzed for transgene EGFP presence by RRT-PCR. The percentages
listed in the column represent the ratio of gene copies for modified
virus to the gene copies for native virus. (A), Native NDFL-EGFP
injected; (B), Modified NDFL-EGFP/·HN-IL-2 injected.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 5. Establishment of a quantification test of EGFP transgene by RRT-PCR. Amplification plots (a) and dissociation curves (b) for EGFP and mouse ß-actin
were derived from Eb-M7 (IL-2R·+) cells infected with NDFL-EGFP. (c), Comparison of amplification efficiencies of EGFP and ß-actin was done in separate
tubes, which were derived from a series of six 1:5 dilutions of the template similar as (a) and (b).
currently being developed as a novel class of anti-tumor agents
either as a viral vector or as an oncolytic agent (21-23). Our
previous in vitro studies showed that lentogenic recombinant
NDV with monocyclic replication properties can be retargeted
to the IL-2R+ human leukemia-like cell line, MT-2, by
·HN-IL-2, while the native tropism via the interaction between
HN proteins and sialic-acid containing receptors was abolished
(16). Furthermore, we demonstrated that EGFP transgene
expression was retargeted to MT-2 by NDFL-EGFP via
·HN-IL-2 ex vivo and that virus hemadsorption was inhibited
by ·HN-IL-2 in vivo (17). To prove the principle of virus re-
targeting in vivo, we first had to establish a model consisting
of target-positive and target-negative tumor cell lines. For this
purpose, we selected two cell populations, Eb-M7 (IL-2R·+)
and Eb-M7 (IL-2R·-) out of the parental p11-R-Eb cells.
DBA/2 mice inoculated s.c. with 5x106 Eb-M7 (IL-2R·+) and
1x107 Eb-M7 (IL-2R·-) cells developed similar tumors of
0.5-cm diameter on their flanks at 1 week. IHC staining
demonstrated a similar difference of IL-2R· expression in vitro
(data not shown).
Despite the fact that our bispecific fusion protein ·HN-IL-2
was constructed from the human IL-2 sequence, FACS analysis
showed specific binding of ·HN-IL-2 to the murine IL-2R+
Eb cell line (data not shown). Human and murine IL-2 show
a high sequence homology (62%). We demonstrated that
16.5% of mouse IL-2R+ p11-R-Eb cells were retargeted by
modified NDFL-EGFP/·HN-IL-2 to express the EGFP trans-
gene in comparison to native NDFL-EGFP. The value was
improved to 52.7% when using the IL-2R·-high expression
cell line, Eb-M7 (IL-2R·+). This indicates that the percentage
of retargeted EGFP expression was proportional to the amount
of the IL-2R molecules on the cell surface. We did not observe
retargeted EGFP expression in Eb-M7 (IL-2R·-) cells by
modified NDFL-EGFP/·HN-IL-2, thus corroborating the
previous results obtained with the human IL-2R- Jurkat cell
line (16,17).
Ex vivo infection of Eb-M7 (IL-2R·+) and Eb-M7 (IL-2R·-)
cells either with NDFL-EGFP or with NDFL-EGFP/·HN-IL-2
in DBA/2 mice showed 41.8% of retargeted EGFP delivered
by NDFL-EGFP/·HN-IL-2 in Eb-M7 (IL-2R·+) cells in
comparison to native NDFL-EGFP, and only 2.0% in Eb-M7
(IL-2R·-) cells. The percentage of retargeted EGFP delivery
to Eb-M7 (IL-2R+) cells was 2.0-fold higher when compared
with human IL-2R+ MT-2 cells (17).
After intratumoral injection of the modified virus into
Eb-M7 (IL-2R·+) tumors, the retargeted binding in vivo of
NDFL-EGFP/·HN-IL-2 to the cell membrane and virus
replication in the cytoplasm were visualized by IHC at 1 and
24 h of post-injection, respectively. Necrotic areas were seen at
24 h in tumor sections, demonstrating the efficiency of this
approach of tumor treatment. Ebert et al reported on GFP
expression in tumors injected with recombinant VSV-GFP as a
proof for viral replication (24). We saw no EGFP fluorescence
in tumors dissected at 1 h (data not shown). The results are
consistent with IHC staining which showed the binding of
virus to the cell membranes. The EGFP fluorescence was
observed in tumor sections dissected at 24 h, in which re-
targeted EGFP expression was evident impressively in Eb-M7
(IL-2R·+) tumors, but not in Eb-M7 (IL-2R·-) tumors. These
results manifested that recombinant NDV can be retargeted
to defined tumors by bispecific fusion proteins in vivo, causing
tumor destruction via virus replication.
Several studies (20,25,26) employed real-time PCR to
quantify EGFP or GFP transgene expression. To quantify
EGFP expression in vivo, we also applied RRT-PCR in this
study. Relative to native NDFL-EGFP, high amounts of the
EGFP gene was transferred by modified NDFL-EGFP/
·HN-IL-2 upon intratumoral inoculation of Eb-M7 (IL-2R·+)
tumors. RRT-PCR confirmed that only very low amounts of
the EGFP gene was delivered by NDFL-EGFP/·HN-IL-2 to
Eb-M7 (IL-2R·-) tumors.
We showed before that NDFL-EGFP viral replication
accompanied by EGFP expression can serve as a surrogate
maker for virus replication (17). Here, it is the first time that
we evaluated the biodistribution of lentogenic NDV in
tumor-bearing mice by RRT-PCR. By quantifying EGFP
mRNA levels, we found that NDV can replicate in all the
tested tissues (tumor, liver, spleen, lung, spleen and thymus).
Among them, lung had the highest amounts of virus
accumulation which may not be surprising after i.v.
inoculation of the virus. The tissue tropism of the same strain
NDFL-EGFP has been investigated in 14-day-old embryo-
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Table II. Biodistribution of the transgene EGFP by RRT-
PCR after i.v. injection of native or modified NDFL-EGFP.
–––––––––––––––––––––––––––––––––––––––––––––––––
Tissue EGFP copies % retargeted EGFP
expression
–––––––––––––––––––––––––––––––––––––––––––––––––
(A) native virus
Tumor (IL-2R·+) 44453.2
Tumor (IL-2R·-) 24322.4
Liver 2511294.9
Spleen 1070608.8
Kidney 237900.7
Lung 30876374.0
Thymus 4372418.3
(B) modified virus
Tumor (IL-2R·+) 43538.4 97.9
Tumor (IL-2R·-) 6841.0 28.1
Liver 189258.7 7.5
Spleen 696614.0 65.1
Kidney 9674.7 4.1
Lung 299044.4 0.0
Thymus 172950.5 4.0
–––––––––––––––––––––––––––––––––––––––––––––––––
DBA/2 mice bearing both Eb-M7 (IL-2R·+) and Eb-M7 (IL-2R·-)
tumors (0.3-0.4 cm) on their right and left flanks respectively
received i.v. 5000 HU of native NDFL-EGFP or modified NDFL-
EGFP/·HN-IL-2. After 24 h, mice were perfused transcardially
through the aorta with DEPC-treated PBS until lung, liver and
kidney turned pale. Tumors and organs of interest were analyzed
for the presence of the EGFP transgene by RRT-PCR. The
percentages listed in the column represent the ratio of the number of
gene copies for modified virus to the number of gene copies for
native virus. (A), Native NDFL-EGFP injected; (B), Modified
NDFL-EGFP/·HN-IL-2 injected.
–––––––––––––––––––––––––––––––––––––––––––––––––
nated chicken eggs by Al-Garib et al, who observed that lung
and the chorioallantoic membrane were the initial target
organs as determined by fluorescence microscopy (7). It was
also reviewed by Morrison that avirulent NDV results largely
in respiratory tract infections (27). We have shown previously
no replication of NDV in normal resting human T cells or in
IL-2 pre-activated T cells, but replication in a broad spectrum
of human and mouse tumor cells in vitro by flow cytometry
(11). Up to now no data exist about NDV replication in tissues
of mammals. We show here that NDV to some degree can
replicate in the digestive and respiratory tract of mice. Whether
this is accompanied by cell death or tissue destruction is not
known.
After intravenous injection of the modified NDFL-EGFP/
·HN-IL-2 into tumor-bearing mice, Eb-M7 (IL-2R·+) tumors
were the most prominent retargeted tissue. All normal organs
were relatively refractory to this modified virus when compared
to native NDFL-EGFP. These results demonstrate that, upon
systemic delivery, recombinant NDV, when modified by a
bispecific molecule i) can be retargeted to target positive
tumors followed by retargeted transgene expression and ii)
shows decreased side effects on normal tissues.
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